Bibliografía del artículo
1. Singer HS. Current issues in Tourette syndrome. Mov Disord 2000; 15(6):1051-1063.
2. Müller-Vahl KR. The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother 2002; 3(7):899-914.
3. Sandyk R, Awerbuch G. Marijuana and Tourette's Syndrome. J Clin Psychopharmacol 1988; 8(6):444-445.
4. Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 1993; 7(4):389-391.
5. Müller-Vahl KR, Kolbe H, Schneider U, et al. Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiat Scand 1998; 98(6):502-506.
6. Müller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol. Am J Psychiatry 1999; 156(3):495.
7. Müller-Vahl KR, Schneider U, Emrich HM. Combined treatment of Tourette-Syndrome with 9-THC and dopamine receptor antagonists. J Cannabis Therap 2002; 2(3/4):145-154.
8. Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002; 35(2):57-61.
9. Müller-Vahl KR, Schneider U, Prevedel H, et al. Delta9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial. J Clin Psychiatry 2003; 64(4):459-465.
10. Berding G, Müller-Vahl K, Schneider U, et al. [123I]AM281 SPET imaging of central CB1 receptors before and after D9-THC therapy and whole body scanning for assessment of radiation dose in Tourette patients. J Biol Psy 2004; 55(9):904-915.
11. Berding G, Gielow P, Buchert R, et al. I-124-AM281 PET imaging of central cannabinoid CB1 receptors in a schizophrenic patient. Nuklearmedizin 2005; 44:A122.
12. Fankhauser M. History of cannabis use in western medicine. In: Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Grotenhermen F, Russo E (Eds.), Haworth Press, Binghamton (NY) 2002:37-51.
13. Grotenhermen F. Review of therapeutic effects. In: Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Grotenhermen F, Russo E (Eds.), Haworth Press, Binghamton (NY) 2002: 123-142.
14. Leckman JF, Towbin KE, Ort SI, et al. Clinical assessment of tic disorder severity. In: Tourette's syndrome and tic disorders. Cohen DJ, Bruun RD, Leckman JF (Eds.), John Wiley, New York 1988: 55-78.
15. Moss DE, Montgomery SP, Salo AA, et al. Tetrahydrocannabinol effects on extrapyramidal motor behaviors in an animal model of Parkinson's disease. In: The Cannabinoids: chemical, pharmacologic, and therapeutic aspects. Agurell S, Dewey WL, Willette RE (Eds.), Academic Press, New York 1984: 815-828.
16. Moss DE, Manderscheid PZ, Montgomery SP, et al. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 1989; 44(21):1521-1525.
17. Shapiro AK, Shapiro ES, Young JG, et al. Signs, symptoms, and clinical course. In: Gilles de la Tourette Syndrome. Shapiro AK, Shapiro ES, Young JG, et al. (Eds.), Raven Press, 2nd ed., New York 1988 :127-193.
18. Harcherik DF, Leckman JF, Detlor J, et al. A new instrument for clinical studies of Tourette's syndrome. Am J Acad Child Psychiatry 1984; 23(2):153-160.
19. Müller-Vahl KR, Koblenz A, Jöbges M, et al. Influence of delta-9-Tetrahydrocannabinol (D9-THC) treatment of Tourette-Syndrome on neuropsychological testing. Pharmacopsychiatry 2001; 34(1):19-24.
20. Helmstaedter C, Durwen HF. VLMT. Verbaler Lern- und Merkfähigkeitstest. Schweiz. Arch Neurol Psychiatr 1990; 141(1):21-30.
21. Wechsler D. A standardized memory scale for clinical use. J Psychol 1945; 19:87-95.
22. Wechsler D. Die Messung der Intelligenz Erwachsener. Huber Verlag, Bern,1956.
23. Merz J, Lehrl S, Galster JV, et al. MWT-B - ein Intelligenzkurztest. Psychiatr Neurol Med Psychol 1975; 27(7):423-428.
24. Benton AL. A visual retention test for clinical use. Arch Neurol Psychol 1945; 59:273-291.
25. Swets JA, Green DM, Getty DJ, et al. Signal detection and identification at successive stages of observation. Percept Psychopsy 1978; 23(4):275-289.
26. Arnold W. Der Pauli-Test. Springer, Berlin 1975.
27. Zimmermann P, Fimm B. Neuropsychologische Testbatterie zur Erfassung von Aufmerksamkeitsdefiziten. Psychologisches Institut der Universität Freiburg 1989.
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
29. Hamilton M. Development of rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4):278-296.
30. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale - preliminary report. Psychopharmacol Bull 1973; 9(1):13-28.
31. Derogatis LR. SCL 90. Administration, scoring and procedures. Manual-I for the R(evised) version and other instruments of the psychopathology rating scale series. John Hopkins University School of Medicine 1977.
32. Goetz CG, Tanner CM, Wilson RS, et al. A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology 1987; 37(9):1542-1544.
33. Müller-Vahl KR, Prevedel H, Theloe K, et al. Treatment of Tourette-Syndrome with 9-Tetrahydrocannabinol (D9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 2003; 28(2):384-388.
34. Grotenhermen F. Effects of cannabis and cannabinoids. In: Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Grotenhermen F, Russo E (Eds.), Haworth Press, Binghamton (NY) 2002: 55-65.
35. Pope HG Jr, Gruber AJ, Hudson JI, et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58(10):909-915.
36. Pope HJ. Cannabis, cognition, and residual confounding. JAMA 2002; 287(9):1172-1174.
37. Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287(9):1123-1131.
38. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003; 33(1):15-21.
39. Patton GC, Coffey C, Carlin JB, et al. Cannabis use and mental health in young people: cohort study. BMJ 2002; 325(7374):1195-1198.
40. Iversen L. Cannabis and the brain. Brain 2003; 126(Pt 6):1252-1270.
41. Swift W, Hall W. Cannabis and dependence. In: Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Grotenhermen F, Russo E (Eds.), Haworth Press, Binghamton (NY) 2002:257-268.
42. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol®). J Psychoactive Drugs 1998; 30(2):187-196.
43. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2(3):244-268.
44. Kleiber D, Soellner R, Tossmann P. Cannabiskonsum in der Bundesrepublik Deutschland: Entwicklungstendenzen, Konsummuster und Einflußfaktoren. Bonn, Federal Ministry of Health 1997.
45. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298(1):7-14.
46. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74(2):129-180.
47. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77(2):299-318.
48. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87(5):1932-1936.
49. Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis. Lancet Neurol 2003; 2(5):291-298.
50. Beltramo M, de Fonseca FR, Navarro M, et al. Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor. J Neurosci 2000; 20(9):3401-3407.
51. Di Marzo V, Hill MP, Bisogno T, et al. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000; 14(10):1432-1438.
52. Pertwee RG, Greentree SG, Swift PA. Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 1988; 27(12):1265-1270.
53. Moss DE, McMaster SB, Rogers J. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol Biochem Behav 1981; 15(5):779-783.
54. Navarro M, Fernandez-Ruiz JJ, De Miguel R et al. Motor disturbances induced by an acute dose of delta 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol Biochem Behav 1993; 45(2):291-298.
55. Pryor GT, Larsen FF, Husain S, et al. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacol Biochem Behav 1978; 8(3):295-318.
56. Richter A, Loscher W. (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol 1994; 264(3):371-377.
57. Sieradzan KA, Fox SH, Hill M, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001; 57(11):2108-2111.
58. Gadzicki D, Müller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999; 13(4):321-323.
59. Gadzicki D, Müller-Vahl KR, Heller D, et al. Tourette Syndrome is not caused by mutations in the Central Cannabinoid Receptor (CNR1) Gene. Am J Med Gen 2004; 127(1):97-103.
60. Singer HS. Neurobiology of Tourette syndrome. Neurol Clin 1997; 15(2):357-379.
61. Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis. Lancet Neurol 2003; 2(5):291-298.
62. Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 1996; 22(4):382-385.